Compare MRVI & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRVI | DRTS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 559.0M | 641.6M |
| IPO Year | 2020 | N/A |
| Metric | MRVI | DRTS |
|---|---|---|
| Price | $4.83 | $8.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $4.13 | ★ $8.67 |
| AVG Volume (30 Days) | ★ 1.8M | 421.8K |
| Earning Date | 05-07-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.54 | N/A |
| Revenue Next Year | $7.87 | $699.98 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $2.81 |
| 52 Week High | $4.11 | $9.07 |
| Indicator | MRVI | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 80.65 | 59.76 |
| Support Level | $3.27 | $6.47 |
| Resistance Level | N/A | $8.60 |
| Average True Range (ATR) | 0.23 | 0.63 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 98.48 | 66.63 |
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.